Multiple Myeloma | Staging
Item
prior or current diagnosis durie-salmon stage ii or iii multiple myeloma.
boolean
C0026764 (UMLS CUI [1])
C0332305 (UMLS CUI [2])
Serum paraprotein measurement Multiple Myeloma | Urine paraprotein measurement Multiple Myeloma | Specimen Collection 24 Hours
Item
measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).
boolean
C0585639 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
C0585640 (UMLS CUI [2,1])
C0026764 (UMLS CUI [2,2])
C0200345 (UMLS CUI [3,1])
C1442770 (UMLS CUI [3,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status score of 0,1, or 2
boolean
C1520224 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative
Item
females of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430057 (UMLS CUI [2,2])
Dexamethasone High dose | Disease Progression
Item
prior development of disease progression during high-dose dexamethasone containing therapy
boolean
C0011777 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Thalidomide | Rash desquamating
Item
the development of a desquamating rash while taking thalidomide
boolean
C0039736 (UMLS CUI [1])
C0542171 (UMLS CUI [2])
Therapeutic procedure Against Multiple Myeloma | Investigational Therapies Against Multiple Myeloma | Therapies, Investigational
Item
use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment
boolean
C0087111 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
C0949266 (UMLS CUI [2,1])
C0521124 (UMLS CUI [2,2])
C0026764 (UMLS CUI [2,3])
C0949266 (UMLS CUI [3])
LABORATORY ABNORMALITIES | Absolute neutrophil count
Item
laboratory abnormalities: absolute neutrophil count less than 1,000 cells/mm^3
boolean
C1853129 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Platelet Count measurement
Item
laboratory abnormalities: platelet count < 75,000/mm^3
boolean
C1853129 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Creatinine measurement, serum
Item
laboratory abnormalities: serum creatinine > 2.5 mg/dl
boolean
C1853129 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
laboratory abnormalities: serum glutamic oxaloacetic transaminase (sgot)/aspartate aminotransferase (ast) or serum glutamic pyruvic transaminase (sgpt)/alanine aminotransferase (alt) > 3.0 x upper limit of normal
boolean
C1853129 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
LABORATORY ABNORMALITIES | Serum total bilirubin measurement
Item
laboratory abnormalities: serum total bilirubin > 2.0 mg/dl
boolean
C1853129 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
Malignant Neoplasms | Multiple Myeloma
Item
prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for ≥ 3 years.
boolean
C0006826 (UMLS CUI [1])
C0026764 (UMLS CUI [2])